{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neovascular+%28Wet%29+AMD&page=2", "query": { "condition": "Neovascular (Wet) AMD", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neovascular+%28Wet%29+AMD&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-29T22:27:22.804Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07440225", "title": "A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Macular Degeneration", "Age-Related Macular Degeneration", "Choroidal Neovascularization", "Wet Macular Degeneration" ], "interventions": [ { "name": "Tiespectus", "type": "DRUG" }, { "name": "Aflibercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EyeBiotech Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 960, "start_date": "2026-03-27", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-09-29T22:27:22.804Z", "location_count": 66, "location_summary": "Scottsdale, Arizona • Fayetteville, Arkansas • Springdale, Arkansas + 58 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Glendale", "state": "California" }, { "city": "Modesto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07440225" }, { "nct_id": "NCT03249740", "title": "A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neovascular Age-Related Macular Degeneration" ], "interventions": [ { "name": "GB-102", "type": "DRUG" }, { "name": "Aflibercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Graybug Vision", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 32, "start_date": "2017-08-29", "completion_date": "2019-01-16", "has_results": false, "last_update_posted_date": "2019-12-20", "last_synced_at": "2026-09-29T22:27:22.804Z", "location_count": 8, "location_summary": "Gilbert, Arizona • Beverly Hills, California • Indianapolis, Indiana + 5 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Lynbrook", "state": "New York" }, { "city": "Abilene", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03249740" }, { "nct_id": "NCT05989126", "title": "Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetic Macular Edema (DME)", "Neovascular Age-Related Macular Degeneration (nAMD)" ], "interventions": [ { "name": "aflibercept 8 mg PFS", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2024-04-15", "completion_date": "2024-05-31", "has_results": true, "last_update_posted_date": "2026-05-28", "last_synced_at": "2026-09-29T22:27:22.804Z", "location_count": 2, "location_summary": "Bellaire, Texas • The Woodlands, Texas", "locations": [ { "city": "Bellaire", "state": "Texas" }, { "city": "The Woodlands", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05989126" }, { "nct_id": "NCT07496567", "title": "A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Macular Degeneration", "Age-Related Macular Degeneration", "Choroidal Neovascularization", "Wet Macular Degeneration" ], "interventions": [ { "name": "Tiespectus", "type": "DRUG" }, { "name": "Aflibercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EyeBiotech Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 960, "start_date": "2026-04-15", "completion_date": "2028-07-31", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-09-29T22:27:22.804Z", "location_count": 52, "location_summary": "Gilbert, Arizona • Encino, California • Mountain View, California + 49 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Encino", "state": "California" }, { "city": "Mountain View", "state": "California" }, { "city": "Santa Ana", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT07496567" }, { "nct_id": "NCT02461771", "title": "Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neovascular Age-Related Macular Degeneration" ], "interventions": [ { "name": "Pegcetacoplan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Apellis Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 13, "start_date": "2015-01-28", "completion_date": "2016-03-08", "has_results": true, "last_update_posted_date": "2020-10-06", "last_synced_at": "2026-09-29T22:27:22.804Z", "location_count": 3, "location_summary": "Beverly Hills, California • Miami, Florida • Portsmouth, New Hampshire", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Portsmouth", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT02461771" }, { "nct_id": "NCT07064759", "title": "Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neovascular Age-Related Macular Degeneration (nAMD)" ], "interventions": [ { "name": "4D-150 IVT (3E10 vg/eye)", "type": "BIOLOGICAL" }, { "name": "EYLEA® (aflibercept) Injection 2 mg (0.05mL)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "4D Molecular Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 480, "start_date": "2025-07-22", "completion_date": "2029-02", "has_results": false, "last_update_posted_date": "2026-04-16", "last_synced_at": "2026-09-29T22:27:22.804Z", "location_count": 54, "location_summary": "Scottsdale, Arizona • Sun City, Arizona • Tucson, Arizona + 49 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Campbell", "state": "California" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07064759" }, { "nct_id": "NCT04516278", "title": "A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Age-related Macular Degeneration", "Neovascular Age-related Macular Degeneration", "Wet Macular Degeneration", "BRVO - Branch Retinal Vein Occlusion", "Diabetic Macular Edema" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Outlook Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 197, "start_date": "2020-10-01", "completion_date": "2021-02-10", "has_results": true, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-09-29T22:27:22.804Z", "location_count": 20, "location_summary": "Tucson, Arizona • Beverly Hills, California • Glendale, California + 17 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Palm Desert", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04516278" }, { "nct_id": "NCT03022292", "title": "The IAI-OCTA Study; a Study of OCT-Angiography Analysis Efficacy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Wet Macular Degeneration" ], "interventions": [ { "name": "Aflibercept Ophthalmic", "type": "DRUG" }, { "name": "optovue angiovue", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 26, "start_date": "2017-03-30", "completion_date": "2020-08-31", "has_results": true, "last_update_posted_date": "2022-01-06", "last_synced_at": "2026-09-29T22:27:22.804Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03022292" }, { "nct_id": "NCT02061865", "title": "Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neovascular Wet Age-related Macular Degeneration (AMD)" ], "interventions": [ { "name": "REGN2176-3", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 12, "start_date": "2014-02", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2015-02-11", "last_synced_at": "2026-09-29T22:27:22.804Z", "location_count": 4, "location_summary": "Beverly Hills, California • Colorado Springs, Colorado • Boston, Massachusetts + 1 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02061865" }, { "nct_id": "NCT06864988", "title": "4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Macular Neovascularization Secondary to Age-Related Macular Degeneration" ], "interventions": [ { "name": "4D-150 IVT (3E10 vg/eye)", "type": "BIOLOGICAL" }, { "name": "EYLEA® (aflibercept) Injection 2 mg (0.05mL)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "4D Molecular Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 480, "start_date": "2025-03-03", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-09-29T22:27:22.804Z", "location_count": 91, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Springdale, Arkansas + 79 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06864988" } ] }